Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
BGB-A445 is an activating anti-TNFRSF4 (OX40) antibody that does not block binding to its ligand, OX40L, potentially resulting in increased immune response and anti-tumor activity (Journal for ImmunoTherapy of Cancer 2020;8:699).
|DrugClasses||OX40 Antibody 12|
|CAS Registry Number||NA|
|Therapy Name||Drugs||Efficacy Evidence||Clinical Trials|
|BGB-A445 + Tislelizumab||BGB-A445 Tislelizumab||0||1|